Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Impact of Ct-DNA MRD-Guided Adjuvant Therapy on Outcomes in Resectable Pancreatic Cancer

NCT06966440 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06966440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06966440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Impact of Ct-DNA MRD-Guided Adjuvant Therapy on Outcomes in Resectable Pancreatic Cancer
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
June 1, 2025
Completion date
June 1, 2030
Enrollment
856 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma resectable